trpv4  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Alomone Labs trpv4
    FD20 content in serum. In Ctrl and DU groups, after treatment with <t>TRPV4</t> agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Trpv4, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 38 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/trpv4/product/Alomone Labs
    Average 95 stars, based on 38 article reviews
    Price from $9.99 to $1999.99
    trpv4 - by Bioz Stars, 2022-12
    95/100 stars

    Images

    1) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    2) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    3) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    4) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    5) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    6) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    7) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    8) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    9) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    10) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    11) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    12) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    13) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    14) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    15) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    16) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    17) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    18) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    19) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    20) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    21) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    22) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    23) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    24) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    25) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    26) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    27) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    28) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    29) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    30) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    31) Product Images from "Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers"

    Article Title: Role of TRPV4 in the Diagnosis and Treatment of Helicobacter pylori Infection in Children with Duodenal Ulcers

    Journal: BioMed Research International

    doi: 10.1155/2022/2777882

    FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: FD20 content in serum. In Ctrl and DU groups, after treatment with TRPV4 agonist GSK1016790 A or inhibitor HC067047, the content of FD20 in serum was detected. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: The content of inflammatory factor TNF- α in tissues and serum. (a) In the Ctrl and DU groups, serum TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. (b) In the Ctrl and DU groups, duodenal tissue TNF- α content changes after treatment with TRPV4 agonists GSK1016790 A or inhibitor HC067047. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used:

    TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P
    Figure Legend Snippet: TRPV4 is highly expressed in children with duodenal ulcer and has good diagnostic value. (a) and (b) Immunohistochemistry representative images (a) and summary (b) data showing the expression of TRPV4 in children with duodenal ulcer; Ctrl: nonduodenal ulcer; DU: duodenal ulcer. (c) ROC curve analyses of TRPV4. n = 11, ∗ P

    Techniques Used: Diagnostic Assay, Immunohistochemistry, Expressing

    Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P
    Figure Legend Snippet: Increased TRPV4 expression and enhanced calcium influx in duodenal ulcer mice. (a) Representative images showing hematoxylin-eosin staining of duodenum tissue. (b) and (c) Representative images (b) and summary (c) data showing the expression of TRPV4 in duodenal ulcer mice. (d) and (e) Representative traces (d) and summarized data (e) showing the changes in the intracellular Ca 2+ concentration of duodenal tissue between DU and Ctrl group. Ctrl: nonduodenal ulcer; DU: duodenal ulcer. n = 3, ∗ P

    Techniques Used: Expressing, Mouse Assay, Staining, Concentration Assay

    32) Product Images from "Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension"

    Article Title: Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension

    Journal: Journal of Lipid Research

    doi: 10.1016/j.jlr.2021.100145

    Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.
    Figure Legend Snippet: Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.

    Techniques Used: Western Blot, Isolation, Expressing, Immunoprecipitation, Immunohistochemistry, Immunolabeling

    Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P
    Figure Legend Snippet: Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P

    Techniques Used: Expressing

    Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P
    Figure Legend Snippet: Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P

    Techniques Used: Immunolabeling, Incubation

    Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P
    Figure Legend Snippet: Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P

    Techniques Used: Fluorescence

    33) Product Images from "Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension"

    Article Title: Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension

    Journal: Journal of Lipid Research

    doi: 10.1016/j.jlr.2021.100145

    Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.
    Figure Legend Snippet: Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.

    Techniques Used: Western Blot, Isolation, Expressing, Immunoprecipitation, Immunohistochemistry, Immunolabeling

    Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P
    Figure Legend Snippet: Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P

    Techniques Used: Expressing

    Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P
    Figure Legend Snippet: Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P

    Techniques Used: Immunolabeling, Incubation

    Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P
    Figure Legend Snippet: Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P

    Techniques Used: Fluorescence

    34) Product Images from "Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension"

    Article Title: Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension

    Journal: Journal of Lipid Research

    doi: 10.1016/j.jlr.2021.100145

    Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.
    Figure Legend Snippet: Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.

    Techniques Used: Western Blot, Isolation, Expressing, Immunoprecipitation, Immunohistochemistry, Immunolabeling

    Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P
    Figure Legend Snippet: Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P

    Techniques Used: Expressing

    Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P
    Figure Legend Snippet: Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P

    Techniques Used: Immunolabeling, Incubation

    Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P
    Figure Legend Snippet: Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P

    Techniques Used: Fluorescence

    35) Product Images from "Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension"

    Article Title: Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension

    Journal: Journal of Lipid Research

    doi: 10.1016/j.jlr.2021.100145

    Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.
    Figure Legend Snippet: Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.

    Techniques Used: Western Blot, Isolation, Expressing, Immunoprecipitation, Immunohistochemistry, Immunolabeling

    Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P
    Figure Legend Snippet: Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P

    Techniques Used: Expressing

    Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P
    Figure Legend Snippet: Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P

    Techniques Used: Immunolabeling, Incubation

    Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P
    Figure Legend Snippet: Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P

    Techniques Used: Fluorescence

    36) Product Images from "Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension"

    Article Title: Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension

    Journal: Journal of Lipid Research

    doi: 10.1016/j.jlr.2021.100145

    Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.
    Figure Legend Snippet: Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.

    Techniques Used: Western Blot, Isolation, Expressing, Immunoprecipitation, Immunohistochemistry, Immunolabeling

    Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P
    Figure Legend Snippet: Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P

    Techniques Used: Expressing

    Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P
    Figure Legend Snippet: Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P

    Techniques Used: Immunolabeling, Incubation

    Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P
    Figure Legend Snippet: Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P

    Techniques Used: Fluorescence

    37) Product Images from "Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension"

    Article Title: Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension

    Journal: Journal of Lipid Research

    doi: 10.1016/j.jlr.2021.100145

    Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.
    Figure Legend Snippet: Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.

    Techniques Used: Western Blot, Isolation, Expressing, Immunoprecipitation, Immunohistochemistry, Immunolabeling

    Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P
    Figure Legend Snippet: Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P

    Techniques Used: Expressing

    Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P
    Figure Legend Snippet: Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P

    Techniques Used: Immunolabeling, Incubation

    Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P
    Figure Legend Snippet: Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P

    Techniques Used: Fluorescence

    38) Product Images from "Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension"

    Article Title: Membrane cholesterol regulates TRPV4 function, cytoskeletal expression, and the cellular response to tension

    Journal: Journal of Lipid Research

    doi: 10.1016/j.jlr.2021.100145

    Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.
    Figure Legend Snippet: Most membrane TRPV4 does not partition into raft domains or interact with caveolar proteins. A: Western blot; detergent-free lipid raft isolation in primary TM cells. The supernatant fraction contains cytosolic proteins; fractions 1 and 2 (5% sucrose) contain nonlipid-raft membrane proteins, fractions 3–6 (5–35% sucrose) contain lipid raft membranes, and fractions 7 and 8 (pellet, 45% sucrose) contain unsuspended proteins and cell nuclei. TRPV4 protein is predominantly confined to fraction 2; fraction 4 is associated with flotillin-1 (48 kDa) and Cav-1 (22 kDa), whereas the supernatant/cytosol fraction associates with α-SMA (42 kDa). B: Coimmunoprecipitation. TRPV4-Cav-1 interaction assessed with the Cav-1 antibody for TRPV4 pulldown in control, MβCD, and MβCD:cholesterol-treated samples. Input bands, whole-cell lysate; bound bands, Cav-1-bound protein fraction; unbound bands, flow-through fractions. Cav-1-bound fractions show modest precipitation of the ∼75 kDa TRPV4 isoform. The absence of Cav-1 expression in unbound fractions confirms the quantitative immunoprecipitation of Cav-1. C, D: Immunohistochemistry, for control, MβCD, and MβCD:cholesterol-treated cells. C: Double immunolabeling for TRPV4 and Cav-1. TRPV4-ir (red arrowheads) does not colocalize with Cav1-ir puncta (green). D: Double immunolabeling for TRPV4 and flotillin. TRPV4-ir (red puncta) does not colocalize with flotillin-ir puncta (green). The inset is shown at higher magnification insets as supplemental Fig. S3 . The scale bar represents 20 μm.

    Techniques Used: Western Blot, Isolation, Expressing, Immunoprecipitation, Immunohistochemistry, Immunolabeling

    Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P
    Figure Legend Snippet: Cholesterol depletion enhances TRPV4-mediated membrane currents in Xenopus oocytes. A: Representative current traces from TRPV4-expressing oocytes and uninjected control oocytes in control solution or after 45 min exposure to 50 μM MβCD. B: I/V curves of TRPV4-expressing oocytes exposed to control solution or MβCD, with uninjected oocytes in inset. Summarized currents obtained at −85 mV are shown in the lower inset. The magnitude of TRPV4-mediated currents (at V m = −85 mV) was compared using Student's t -test. ∗∗ P

    Techniques Used: Expressing

    Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P
    Figure Legend Snippet: Cholesterol depletion increases the number of TRPV4-ir puncta. TRPV4 immunolabeling of primary TM cells. Representative examples of (A) control, (B) 1 h treatment with MβCD, and (C) 1 h treatment with MβCD:cholesterol. Inset: zoomed-in region with TRPV4-ir puncta (arrow). D: Summary of three independent experiments, normalized for control cells. The number of TRPV4 puncta is upregulated after incubation with MβCD. ∗ P

    Techniques Used: Immunolabeling, Incubation

    Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P
    Figure Legend Snippet: Cholesterol depletion increases the amplitude of TRPV4 agonist-induced Ca 2+ signals. A, B: Ratiometric signals in Fura-2 AM-loaded cells. A: GSK101-induced elevations are increased in MβCD-treated cells (n = 8–10). B: Averaged data. MβCD (blue bar) augmented, whereas MβCD:cholesterol (green bar) reduced the amplitude of agonist-induced fluorescence. C: Fluorimetry, cell populations in 96 wells. About 5 nM GSK101 increased Fluo-4 fluorescence. Its effect was facilitated (∼12%) by MβCD (N = 4). ∗∗ P

    Techniques Used: Fluorescence

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96
    Alomone Labs anti trpv4 antibody
    siRNA knockdown supports <t>TRPV4</t> functional expression in BeWo cells. ( A ) Representative Ca 2+ imaging in BeWo cells transfected with scrambled siRNA and TRPV4 siRNAs. Calbryte 590 was used to monitor cytosolic Ca 2+ dynamics. All fluorescence images are the representatives of at least three biological replicates. ( B ) Quantification of GSK101-induced Ca 2+ influx in BeWo cells transfected with scrambled siRNA (n=50), TRPV4 siRNA2 (n=55), or siRNA4 (n=51) from at least three biological replicates. Values represent mean ± SEM and statistics were done using two-way ANOVA followed by Tukey’s test (**: p
    Anti Trpv4 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti trpv4 antibody/product/Alomone Labs
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti trpv4 antibody - by Bioz Stars, 2022-12
    96/100 stars
      Buy from Supplier

    Image Search Results


    siRNA knockdown supports TRPV4 functional expression in BeWo cells. ( A ) Representative Ca 2+ imaging in BeWo cells transfected with scrambled siRNA and TRPV4 siRNAs. Calbryte 590 was used to monitor cytosolic Ca 2+ dynamics. All fluorescence images are the representatives of at least three biological replicates. ( B ) Quantification of GSK101-induced Ca 2+ influx in BeWo cells transfected with scrambled siRNA (n=50), TRPV4 siRNA2 (n=55), or siRNA4 (n=51) from at least three biological replicates. Values represent mean ± SEM and statistics were done using two-way ANOVA followed by Tukey’s test (**: p

    Journal: eLife

    Article Title: Functional coupling between TRPV4 channel and TMEM16F modulates human trophoblast fusion

    doi: 10.7554/eLife.78840

    Figure Lengend Snippet: siRNA knockdown supports TRPV4 functional expression in BeWo cells. ( A ) Representative Ca 2+ imaging in BeWo cells transfected with scrambled siRNA and TRPV4 siRNAs. Calbryte 590 was used to monitor cytosolic Ca 2+ dynamics. All fluorescence images are the representatives of at least three biological replicates. ( B ) Quantification of GSK101-induced Ca 2+ influx in BeWo cells transfected with scrambled siRNA (n=50), TRPV4 siRNA2 (n=55), or siRNA4 (n=51) from at least three biological replicates. Values represent mean ± SEM and statistics were done using two-way ANOVA followed by Tukey’s test (**: p

    Article Snippet: The immunofluorescence of TRPV4 colocalizes with anti-Flag signals in the TRPV4-Flag transfected cells (Figure S2A) but not in the untransfected cells (Figure S2B), validating the specificity of this anti-TRPV4 antibody.

    Techniques: Functional Assay, Expressing, Imaging, Transfection, Fluorescence

    Ca 2+ influx through TRPV4 activates TMEM16F scramblase (left) and siRNA knockdown of TRPV4 (right) abolishes GSK101-induced ca 2+ influx and subsequent TMEM16F CaPLSase activation.

    Journal: eLife

    Article Title: Functional coupling between TRPV4 channel and TMEM16F modulates human trophoblast fusion

    doi: 10.7554/eLife.78840

    Figure Lengend Snippet: Ca 2+ influx through TRPV4 activates TMEM16F scramblase (left) and siRNA knockdown of TRPV4 (right) abolishes GSK101-induced ca 2+ influx and subsequent TMEM16F CaPLSase activation.

    Article Snippet: The immunofluorescence of TRPV4 colocalizes with anti-Flag signals in the TRPV4-Flag transfected cells (Figure S2A) but not in the untransfected cells (Figure S2B), validating the specificity of this anti-TRPV4 antibody.

    Techniques: Activation Assay

    TRPV4 knockout (KO) placentas do not show obvious defects in trophoblast syncytialization in mice. ( A, B ) Representative images of placentas from wild-type (WT) ( A ) and TRPV4 KO ( B ) mice at E18.5. ( C ) Anatomical diagram of fetomaternal exchange in mouse placentas. ( D, E ) MCT1 and MCT4 immunofluorescence staining of the TRPV4 WT ( D ) and KO ( E ) placentas at E18.5. MCT1 (red) specifically stains the SynT-1 layer that faces maternal blood sinuses, while MCT4 (green) specifically stains the SynT-2 layer that encloses fetal blood vessels. Panels ( i–iv ) at the bottom show enlarged views of the placentas on top. All fluorescence images are the representatives of at least three biological replicates.

    Journal: eLife

    Article Title: Functional coupling between TRPV4 channel and TMEM16F modulates human trophoblast fusion

    doi: 10.7554/eLife.78840

    Figure Lengend Snippet: TRPV4 knockout (KO) placentas do not show obvious defects in trophoblast syncytialization in mice. ( A, B ) Representative images of placentas from wild-type (WT) ( A ) and TRPV4 KO ( B ) mice at E18.5. ( C ) Anatomical diagram of fetomaternal exchange in mouse placentas. ( D, E ) MCT1 and MCT4 immunofluorescence staining of the TRPV4 WT ( D ) and KO ( E ) placentas at E18.5. MCT1 (red) specifically stains the SynT-1 layer that faces maternal blood sinuses, while MCT4 (green) specifically stains the SynT-2 layer that encloses fetal blood vessels. Panels ( i–iv ) at the bottom show enlarged views of the placentas on top. All fluorescence images are the representatives of at least three biological replicates.

    Article Snippet: The immunofluorescence of TRPV4 colocalizes with anti-Flag signals in the TRPV4-Flag transfected cells (Figure S2A) but not in the untransfected cells (Figure S2B), validating the specificity of this anti-TRPV4 antibody.

    Techniques: Knock-Out, Mouse Assay, Immunofluorescence, Staining, Fluorescence

    Immunofluorescence of TRPV4 in BeWo cells transfected with TRPV4 siRNAs. Representative immunofluorescence of TRPV4 (red) in scrambled control siRNA and TRPV4 siRNA knockdown BeWo cells. The nuclei were stained with Hoechst (blue). The plasma membrane was labeled with WGA dye (green). All fluorescence images are the representatives of at least three biological replicates.

    Journal: eLife

    Article Title: Functional coupling between TRPV4 channel and TMEM16F modulates human trophoblast fusion

    doi: 10.7554/eLife.78840

    Figure Lengend Snippet: Immunofluorescence of TRPV4 in BeWo cells transfected with TRPV4 siRNAs. Representative immunofluorescence of TRPV4 (red) in scrambled control siRNA and TRPV4 siRNA knockdown BeWo cells. The nuclei were stained with Hoechst (blue). The plasma membrane was labeled with WGA dye (green). All fluorescence images are the representatives of at least three biological replicates.

    Article Snippet: The immunofluorescence of TRPV4 colocalizes with anti-Flag signals in the TRPV4-Flag transfected cells (Figure S2A) but not in the untransfected cells (Figure S2B), validating the specificity of this anti-TRPV4 antibody.

    Techniques: Immunofluorescence, Transfection, Staining, Labeling, Whole Genome Amplification, Fluorescence

    Validation of the TRPV4 antibody for immunofluorescence. ( A, B ) Validation of the TRPV4 antibody in HEK293T cells heterologously expressing a Flag-tagged TRPV4 plasmid. Immunofluorescence of TRPV4 (anti-TRPV4, green) and Flag tag (anti-Flag, red) in HEK293T cells transfected with a Flag-tagged TRPV4 plasmid ( A ) and non-transfected control ( B ). DAPI-stained nuclei are shown in blue. ( C ) Representative immunofluorescence of TRPV4 (green) in BeWo cells. The nuclei were stained with Hoechst (blue) and a plasma membrane marker, FM1-43 dye, is shown in red. All fluorescence images are the representatives of at least three biological replicates.

    Journal: eLife

    Article Title: Functional coupling between TRPV4 channel and TMEM16F modulates human trophoblast fusion

    doi: 10.7554/eLife.78840

    Figure Lengend Snippet: Validation of the TRPV4 antibody for immunofluorescence. ( A, B ) Validation of the TRPV4 antibody in HEK293T cells heterologously expressing a Flag-tagged TRPV4 plasmid. Immunofluorescence of TRPV4 (anti-TRPV4, green) and Flag tag (anti-Flag, red) in HEK293T cells transfected with a Flag-tagged TRPV4 plasmid ( A ) and non-transfected control ( B ). DAPI-stained nuclei are shown in blue. ( C ) Representative immunofluorescence of TRPV4 (green) in BeWo cells. The nuclei were stained with Hoechst (blue) and a plasma membrane marker, FM1-43 dye, is shown in red. All fluorescence images are the representatives of at least three biological replicates.

    Article Snippet: The immunofluorescence of TRPV4 colocalizes with anti-Flag signals in the TRPV4-Flag transfected cells (Figure S2A) but not in the untransfected cells (Figure S2B), validating the specificity of this anti-TRPV4 antibody.

    Techniques: Immunofluorescence, Expressing, Plasmid Preparation, FLAG-tag, Transfection, Staining, Marker, Fluorescence

    Pharmacological inhibition of TRPV4 abolishes GSK101-induced Ca 2+ influx and subsequent TMEM16F activation in BeWo cells. ( A ) Representative images Ca 2+ and PS exposure in BeWo cells treated with 20 nM TRPV4 agonist GSK101 and by 500 nM TRPV4 antagonist GSK219. Ca 2+ dye (Calbryte 488) and fluorescently tagged AnV proteins (AnV-CF594) were used to measure the dynamics of intracellular Ca 2+ and PS externalization, respectively. ( B, C ) Time course of intracellular Ca 2+ ( B ) and PS exposure ( C ) in BeWo cells treated with 20 nM GSK101 and by 500 nM GSK219. n=9. All fluorescence images are the representatives of at least three biological replicates. AnV, Annexin V.

    Journal: eLife

    Article Title: Functional coupling between TRPV4 channel and TMEM16F modulates human trophoblast fusion

    doi: 10.7554/eLife.78840

    Figure Lengend Snippet: Pharmacological inhibition of TRPV4 abolishes GSK101-induced Ca 2+ influx and subsequent TMEM16F activation in BeWo cells. ( A ) Representative images Ca 2+ and PS exposure in BeWo cells treated with 20 nM TRPV4 agonist GSK101 and by 500 nM TRPV4 antagonist GSK219. Ca 2+ dye (Calbryte 488) and fluorescently tagged AnV proteins (AnV-CF594) were used to measure the dynamics of intracellular Ca 2+ and PS externalization, respectively. ( B, C ) Time course of intracellular Ca 2+ ( B ) and PS exposure ( C ) in BeWo cells treated with 20 nM GSK101 and by 500 nM GSK219. n=9. All fluorescence images are the representatives of at least three biological replicates. AnV, Annexin V.

    Article Snippet: The immunofluorescence of TRPV4 colocalizes with anti-Flag signals in the TRPV4-Flag transfected cells (Figure S2A) but not in the untransfected cells (Figure S2B), validating the specificity of this anti-TRPV4 antibody.

    Techniques: Inhibition, Activation Assay, Fluorescence

    Simultaneous imaging of Ca 2+ increase and phospholipid scrambling in TMEM16F knockout (KO) BeWo cells in response to low concentration GSK101. ( A ) Stimulation of TRPV4 with low concentration of GSK101 (0.2 nM) triggers transient Ca 2+ increase without spatiotemporal PS exposure in TMEM16F KO BeWo cells. Ca 2+ dye (Calbryte 594) and fluorescently tagged AnV proteins (AnV-CF488) were used to measure the dynamics of intracellular Ca 2+ and PS externalization, respectively. All fluorescence images are the representatives of at least three biological replicates. ( B ) The dynamics of Ca 2+ (black) and AnV signal (red) of a TMEM16F KO BeWo cell in ( A ) (*). AnV, Annexin V.

    Journal: eLife

    Article Title: Functional coupling between TRPV4 channel and TMEM16F modulates human trophoblast fusion

    doi: 10.7554/eLife.78840

    Figure Lengend Snippet: Simultaneous imaging of Ca 2+ increase and phospholipid scrambling in TMEM16F knockout (KO) BeWo cells in response to low concentration GSK101. ( A ) Stimulation of TRPV4 with low concentration of GSK101 (0.2 nM) triggers transient Ca 2+ increase without spatiotemporal PS exposure in TMEM16F KO BeWo cells. Ca 2+ dye (Calbryte 594) and fluorescently tagged AnV proteins (AnV-CF488) were used to measure the dynamics of intracellular Ca 2+ and PS externalization, respectively. All fluorescence images are the representatives of at least three biological replicates. ( B ) The dynamics of Ca 2+ (black) and AnV signal (red) of a TMEM16F KO BeWo cell in ( A ) (*). AnV, Annexin V.

    Article Snippet: The immunofluorescence of TRPV4 colocalizes with anti-Flag signals in the TRPV4-Flag transfected cells (Figure S2A) but not in the untransfected cells (Figure S2B), validating the specificity of this anti-TRPV4 antibody.

    Techniques: Imaging, Knock-Out, Concentration Assay, Fluorescence

    Lack of TRPV4-TMEM16F coupling in BeWo trophoblast cells in the absence of GSK101. ( A ) Outside-out patch recording of BeWo cells in the absence of GSK101. (1) 0 extracellular Ca 2+ ; (2) 2.5 mM extracellular Ca 2+ . 0.2 mM EGTA was included in the pipette. ( B ) Comparison of outside-out patch current with ( Figure 5B , #2, with 2.5 mM Ca 2+ ) and without GSK101 after 1 s of pre-pulse. ( C ) Comparison of outside-out patch current with ( Figure 5B , #1, with 0 Ca 2+ ) and without GSK101 after 1 s of pre-pulse. Values represent mean ± SEM and statistics were done using Student’s t-test (n=5, ****: p

    Journal: eLife

    Article Title: Functional coupling between TRPV4 channel and TMEM16F modulates human trophoblast fusion

    doi: 10.7554/eLife.78840

    Figure Lengend Snippet: Lack of TRPV4-TMEM16F coupling in BeWo trophoblast cells in the absence of GSK101. ( A ) Outside-out patch recording of BeWo cells in the absence of GSK101. (1) 0 extracellular Ca 2+ ; (2) 2.5 mM extracellular Ca 2+ . 0.2 mM EGTA was included in the pipette. ( B ) Comparison of outside-out patch current with ( Figure 5B , #2, with 2.5 mM Ca 2+ ) and without GSK101 after 1 s of pre-pulse. ( C ) Comparison of outside-out patch current with ( Figure 5B , #1, with 0 Ca 2+ ) and without GSK101 after 1 s of pre-pulse. Values represent mean ± SEM and statistics were done using Student’s t-test (n=5, ****: p

    Article Snippet: The immunofluorescence of TRPV4 colocalizes with anti-Flag signals in the TRPV4-Flag transfected cells (Figure S2A) but not in the untransfected cells (Figure S2B), validating the specificity of this anti-TRPV4 antibody.

    Techniques: Transferring

    TRPV4 and TMEM16F are spatially close to each other on BeWo cell membrane.

    Journal: eLife

    Article Title: Functional coupling between TRPV4 channel and TMEM16F modulates human trophoblast fusion

    doi: 10.7554/eLife.78840

    Figure Lengend Snippet: TRPV4 and TMEM16F are spatially close to each other on BeWo cell membrane.

    Article Snippet: The immunofluorescence of TRPV4 colocalizes with anti-Flag signals in the TRPV4-Flag transfected cells (Figure S2A) but not in the untransfected cells (Figure S2B), validating the specificity of this anti-TRPV4 antibody.

    Techniques:

    4α-phorbol-12, 13-didecanoate (4α-PDD, 20 μM), a TRPV4 agonist, triggers intracellular Ca 2+ elevation in BeWo cells. ( A ) Ca 2+ dye (Calbryte 520, green) was used to monitor the dynamics of intracellular Ca 2+ . All fluorescence images are the representatives of at least three biological replicates. ( B ) Time course of 4α-PDD triggered Ca 2+ influx in BeWo cells (n=7).

    Journal: eLife

    Article Title: Functional coupling between TRPV4 channel and TMEM16F modulates human trophoblast fusion

    doi: 10.7554/eLife.78840

    Figure Lengend Snippet: 4α-phorbol-12, 13-didecanoate (4α-PDD, 20 μM), a TRPV4 agonist, triggers intracellular Ca 2+ elevation in BeWo cells. ( A ) Ca 2+ dye (Calbryte 520, green) was used to monitor the dynamics of intracellular Ca 2+ . All fluorescence images are the representatives of at least three biological replicates. ( B ) Time course of 4α-PDD triggered Ca 2+ influx in BeWo cells (n=7).

    Article Snippet: The immunofluorescence of TRPV4 colocalizes with anti-Flag signals in the TRPV4-Flag transfected cells (Figure S2A) but not in the untransfected cells (Figure S2B), validating the specificity of this anti-TRPV4 antibody.

    Techniques: Fluorescence

    TMEM16F CaPLSase and channel activity in BeWo cells is not affected by TRPV4 knockdown. ( A ) Representative images showing 5 μM ionomycin triggers similar levels of PS exposure in scrambled, TPRV4 siRNA2, and siRNA4 knockdown BeWo cells. ( B ) Quantification of ionomycin-induced AnV intensities increase in BeWo cells transfected with scrambled siRNA (n=25), TRPV4 siRNA2 (n=25), or siRNA4 (n=27). All fluorescence images are the representatives of at least three biological replicates. ( C ) Representative TMEM16F current traces from control siRNA and the TRPV4 siRNAs treated BeWo cells recorded with whole-cell patch clamp or patch clamp-lipid scrambling fluorometry (PCLSF). 1000 μM Ca 2+ was included in the pipette solution, and the current was elicited by a voltage step protocol from –100 to +160 mV with holding potential at –60 mV. ( D ) I-V relation of TMEM16F current recorded from the control siRNA and the TRPV4 siRNAs treated BeWo cells. ( E ) Statistics of the TMEM16F current density at +160 mV shown in ( D ). Student’s t-test (ns: not significant, n=7 for control siRNA, n=8 for TRPV4 siRNA2, and n=7 for TRPV4 siRNA4). ( F ) Representative lipid scrambling activities recorded using PCLSF to simultaneously record TMEM16F channel and lipid scramblase activities. The cells are the same ones shown in ( C ). n=3. AnV, Annexin V.

    Journal: eLife

    Article Title: Functional coupling between TRPV4 channel and TMEM16F modulates human trophoblast fusion

    doi: 10.7554/eLife.78840

    Figure Lengend Snippet: TMEM16F CaPLSase and channel activity in BeWo cells is not affected by TRPV4 knockdown. ( A ) Representative images showing 5 μM ionomycin triggers similar levels of PS exposure in scrambled, TPRV4 siRNA2, and siRNA4 knockdown BeWo cells. ( B ) Quantification of ionomycin-induced AnV intensities increase in BeWo cells transfected with scrambled siRNA (n=25), TRPV4 siRNA2 (n=25), or siRNA4 (n=27). All fluorescence images are the representatives of at least three biological replicates. ( C ) Representative TMEM16F current traces from control siRNA and the TRPV4 siRNAs treated BeWo cells recorded with whole-cell patch clamp or patch clamp-lipid scrambling fluorometry (PCLSF). 1000 μM Ca 2+ was included in the pipette solution, and the current was elicited by a voltage step protocol from –100 to +160 mV with holding potential at –60 mV. ( D ) I-V relation of TMEM16F current recorded from the control siRNA and the TRPV4 siRNAs treated BeWo cells. ( E ) Statistics of the TMEM16F current density at +160 mV shown in ( D ). Student’s t-test (ns: not significant, n=7 for control siRNA, n=8 for TRPV4 siRNA2, and n=7 for TRPV4 siRNA4). ( F ) Representative lipid scrambling activities recorded using PCLSF to simultaneously record TMEM16F channel and lipid scramblase activities. The cells are the same ones shown in ( C ). n=3. AnV, Annexin V.

    Article Snippet: The immunofluorescence of TRPV4 colocalizes with anti-Flag signals in the TRPV4-Flag transfected cells (Figure S2A) but not in the untransfected cells (Figure S2B), validating the specificity of this anti-TRPV4 antibody.

    Techniques: Activity Assay, Transfection, Fluorescence, Patch Clamp, Transferring

    TRPV4-KO mice were protected from pancreatic duct ligation–induced fibrosis. ( A and D ) DIC and Bodipy 493/503–stained images of PSCs from TRPV4-KO mice 24 hours after Yoda1 (25 μM). ( B and C ) Mean cell area and Feret’s diameter (max) of PSCs 24 hours after Yoda1 (25 μM) (from 3 experiments with 20 cells each). ( E ) Loss of fat droplets in PSCs following Yoda1 (25 μM) (from 3 experiments and > 100 cells). ( F and G ) Quantification of collagen type I and fibronectin immunostaining in PSCs from TRPV4-KO mice 4 days after Yoda1 (25 μM). ( H and I ) Representative images of collagen type I and fibronectin staining for the data shown in F and G . ( J – M ) Pancreatic duct ligation (PDL) at the tail region of the pancreas induced chronic pancreatitis and fibrosis in WT and TRPV4-KO mice. Eight days after PDL, chronic pancreatitis and fibrosis parameters of the tail region included ( J ) H E staining, ( K ) H E score, ( L ) Masson’s trichrome staining, and ( M ) area of WT and TRPV4-KO mice ( n = 5). Statistical comparisons were made using 2-tailed Student’s t test. *** P ≤ 0.001. Scale bar: 100 μm.

    Journal: JCI Insight

    Article Title: Piezo1-mediated stellate cell activation causes pressure-induced pancreatic fibrosis in mice

    doi: 10.1172/jci.insight.158288

    Figure Lengend Snippet: TRPV4-KO mice were protected from pancreatic duct ligation–induced fibrosis. ( A and D ) DIC and Bodipy 493/503–stained images of PSCs from TRPV4-KO mice 24 hours after Yoda1 (25 μM). ( B and C ) Mean cell area and Feret’s diameter (max) of PSCs 24 hours after Yoda1 (25 μM) (from 3 experiments with 20 cells each). ( E ) Loss of fat droplets in PSCs following Yoda1 (25 μM) (from 3 experiments and > 100 cells). ( F and G ) Quantification of collagen type I and fibronectin immunostaining in PSCs from TRPV4-KO mice 4 days after Yoda1 (25 μM). ( H and I ) Representative images of collagen type I and fibronectin staining for the data shown in F and G . ( J – M ) Pancreatic duct ligation (PDL) at the tail region of the pancreas induced chronic pancreatitis and fibrosis in WT and TRPV4-KO mice. Eight days after PDL, chronic pancreatitis and fibrosis parameters of the tail region included ( J ) H E staining, ( K ) H E score, ( L ) Masson’s trichrome staining, and ( M ) area of WT and TRPV4-KO mice ( n = 5). Statistical comparisons were made using 2-tailed Student’s t test. *** P ≤ 0.001. Scale bar: 100 μm.

    Article Snippet: Cells were immunostained with a rabbit anti–TRPV4 antiserum (Alomone, ACC-034, 1:250; ref. ), rabbit anti–Piezo1 antiserum (Alomone, APC-087, 1:300; ref. ), rabbit anti-fibronectin antibody (Abcam, ab2413), rabbit anti–collagen type I antibody (Abcam, ab34710), or chicken anti-GFAP antibody (Abcam, 4674) for mouse PSCs or rabbit anti-GFAP (Cell Signaling Technology,12389) for human PSCs overnight at 2°C–8°C.

    Techniques: Mouse Assay, Ligation, Staining, Immunostaining

    Piezo1 mediates TRPV4 channel opening in pancreatic stellate cells. ( A ) Immunostaining of GFAP and TRPV4 in human PSCs. ( B ) TRPV4 agonist GSK101 (100 nM) effects on [Ca 2+ ] i in human PSCs with and without the TRPV4 blocker HC067 (1 μM). ( C ) GSK101 (100 nM) effects on [Ca 2+ ] i in PSCs from 3 biological samples were blocked with the TRPV4 antagonist HC067 (1 μM) (from 18 to 37 cells). ( D ) Immunostaining of GFAP and TRPV4 in mouse PSCs. ( E and F ) Traces and graph represent the effects of the TRPV4 agonist GSK101 (100 nM) on [Ca 2+ ] i in mouse PSCs with and without the TRPV4 blocker HC067 (1 μM) (from 18 cells). ( G – I ) Effects of Yoda1 (25 μM) on [Ca 2+ ] i in PSCs from WT and TRPV4-KO mice. ( I ) Statistical analyses of peak and sustained [Ca 2+ ] i elevation (from 24 to 32 cells). The sustained [Ca 2+ ] i elevation was measured at 6 minutes after Yoda1. ( J and K ) Effects of phospholipase A2 blockers AACOCF3 (30 μM) and YM26734 (10 μM) on Yoda1-induced (25 μM) [Ca 2+ ] i in PSCs (from 24 to 26 cells). The sustained calcium rise was measured at 8 minutes after Yoda1 application. ( L – N ) Fluid shear stress (12 dyne/cm 2 ) was applied for 1 minute in PSCs from WT and TRPV4-KO mice and TRPV4-KO mice with GsMTx4 (5 μM). In panels G , H , and L – N , each colored line represents the response of a single cell. ( O ) Quantification of peak [Ca 2+ ] i following shear stress (12 dyne/cm 2 ) for 1 minute in TRPV4-KO PSCs with and without GsMTx4 (from 24 cells). Statistical analyses were calculated using 2-tailed Student’s t test. * P ≤ 0.05 and **** P ≤ 0.0001. Scale bar: 10 μm.

    Journal: JCI Insight

    Article Title: Piezo1-mediated stellate cell activation causes pressure-induced pancreatic fibrosis in mice

    doi: 10.1172/jci.insight.158288

    Figure Lengend Snippet: Piezo1 mediates TRPV4 channel opening in pancreatic stellate cells. ( A ) Immunostaining of GFAP and TRPV4 in human PSCs. ( B ) TRPV4 agonist GSK101 (100 nM) effects on [Ca 2+ ] i in human PSCs with and without the TRPV4 blocker HC067 (1 μM). ( C ) GSK101 (100 nM) effects on [Ca 2+ ] i in PSCs from 3 biological samples were blocked with the TRPV4 antagonist HC067 (1 μM) (from 18 to 37 cells). ( D ) Immunostaining of GFAP and TRPV4 in mouse PSCs. ( E and F ) Traces and graph represent the effects of the TRPV4 agonist GSK101 (100 nM) on [Ca 2+ ] i in mouse PSCs with and without the TRPV4 blocker HC067 (1 μM) (from 18 cells). ( G – I ) Effects of Yoda1 (25 μM) on [Ca 2+ ] i in PSCs from WT and TRPV4-KO mice. ( I ) Statistical analyses of peak and sustained [Ca 2+ ] i elevation (from 24 to 32 cells). The sustained [Ca 2+ ] i elevation was measured at 6 minutes after Yoda1. ( J and K ) Effects of phospholipase A2 blockers AACOCF3 (30 μM) and YM26734 (10 μM) on Yoda1-induced (25 μM) [Ca 2+ ] i in PSCs (from 24 to 26 cells). The sustained calcium rise was measured at 8 minutes after Yoda1 application. ( L – N ) Fluid shear stress (12 dyne/cm 2 ) was applied for 1 minute in PSCs from WT and TRPV4-KO mice and TRPV4-KO mice with GsMTx4 (5 μM). In panels G , H , and L – N , each colored line represents the response of a single cell. ( O ) Quantification of peak [Ca 2+ ] i following shear stress (12 dyne/cm 2 ) for 1 minute in TRPV4-KO PSCs with and without GsMTx4 (from 24 cells). Statistical analyses were calculated using 2-tailed Student’s t test. * P ≤ 0.05 and **** P ≤ 0.0001. Scale bar: 10 μm.

    Article Snippet: Cells were immunostained with a rabbit anti–TRPV4 antiserum (Alomone, ACC-034, 1:250; ref. ), rabbit anti–Piezo1 antiserum (Alomone, APC-087, 1:300; ref. ), rabbit anti-fibronectin antibody (Abcam, ab2413), rabbit anti–collagen type I antibody (Abcam, ab34710), or chicken anti-GFAP antibody (Abcam, 4674) for mouse PSCs or rabbit anti-GFAP (Cell Signaling Technology,12389) for human PSCs overnight at 2°C–8°C.

    Techniques: Immunostaining, Mouse Assay